Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Strengths and Weaknesses Lisa Joseph Sophie Harris
Strengths <ul><li>Original study </li></ul><ul><li>Clear objectives which they achieved </li></ul><ul><li>Used a wide rang...
<ul><li>Good statistical significance in majority of results (p<0.01) </li></ul><ul><li>Valuable research </li></ul><ul><u...
Weaknesses <ul><li>Statistically significant results often achieved at glucose concentrations higher than normal </li></ul...
Points for Discussion <ul><li>Are the results reliable/reproducible? </li></ul><ul><ul><li>2 other separate studies (Brisc...
Result reliability/reproducibility? Itoh Y et al CHO-hGPR40 <300µM Briscoe  CP et al HEK293-hGPR40 >1µM Kotarsky K et al H...
Physiological conditions? <ul><li>Murine pancreatic  β -cell lines – why the differences in GPR40 expression? </li></ul><u...
Intracellular metabolism or GPR40? Poitout 2003
Is it valuable? <ul><li>Kotarsky K et al: </li></ul><ul><ul><li>Thiazolidinedione drugs/anti-obesity drug(e.g. rozaglitazo...
Upcoming SlideShare
Loading in …5
×

Strengths and Weaknesses

932 views

Published on

Published in: Technology, Health & Medicine
  • Be the first to comment

  • Be the first to like this

Strengths and Weaknesses

  1. 1. Strengths and Weaknesses Lisa Joseph Sophie Harris
  2. 2. Strengths <ul><li>Original study </li></ul><ul><li>Clear objectives which they achieved </li></ul><ul><li>Used a wide range of techniques </li></ul><ul><ul><li>Used more than 1 method to show same result </li></ul></ul><ul><ul><li>Results reproducible (n=3/4) </li></ul></ul>
  3. 3. <ul><li>Good statistical significance in majority of results (p<0.01) </li></ul><ul><li>Valuable research </li></ul><ul><ul><li>Potential to develop new therapeutic drugs </li></ul></ul>
  4. 4. Weaknesses <ul><li>Statistically significant results often achieved at glucose concentrations higher than normal </li></ul><ul><li>A lot of data not shown </li></ul><ul><li>Need to analyse direct interactions between FFA’S and GPR40. </li></ul>
  5. 5. Points for Discussion <ul><li>Are the results reliable/reproducible? </li></ul><ul><ul><li>2 other separate studies (Briscoe CP et al [2003], Kotarsky K et al [2003]) </li></ul></ul><ul><ul><li>Different cells, different concentrations </li></ul></ul><ul><ul><li>Disparate EC 50 values </li></ul></ul><ul><li>Are the conditions physiological? </li></ul><ul><li>Is the research valuable? </li></ul><ul><ul><li>Drugs already exist that may target this pathway (Kotarsky et al [2003]) </li></ul></ul>
  6. 6. Result reliability/reproducibility? Itoh Y et al CHO-hGPR40 <300µM Briscoe CP et al HEK293-hGPR40 >1µM Kotarsky K et al HFF11-R10 ‘ appropriate’ Capric acid (C6) 43±2.2 4.85±0.06 12.6±0.4 γ -linolenic acid 4.6±1.6 5.05±0.12 28.5±2.6 Oleic acid 2.0±0.3 4.39 123.1±12
  7. 7. Physiological conditions? <ul><li>Murine pancreatic β -cell lines – why the differences in GPR40 expression? </li></ul><ul><li>FFA concentrations and albumin </li></ul><ul><ul><li>Concentration unbound 1-10nM </li></ul></ul><ul><ul><li>EC 50 for activation higher than this level </li></ul></ul><ul><ul><li>?Local levels higher than plasma levels </li></ul></ul><ul><li>Glucose concentration </li></ul>
  8. 8. Intracellular metabolism or GPR40? Poitout 2003
  9. 9. Is it valuable? <ul><li>Kotarsky K et al: </li></ul><ul><ul><li>Thiazolidinedione drugs/anti-obesity drug(e.g. rozaglitazone) strongly activate this receptor </li></ul></ul><ul><ul><li>Mechanism of action? </li></ul></ul><ul><ul><li>Remaining therapeutic potential? </li></ul></ul>

×